Semiconductor genome sequencing can support the precision therapy of brain tumors by detecting targetable biomarkers

A new study has demonstrated that semiconductor DNA sequencing can identify key genetic mutations in patients with glioblastoma. These mutations may signal weaknesses in the cancer’s armor that clinicians can exploit to improve cancer therapy. The bitter side of conventional cancer therapies is well-known and is the object of much cancer research to develop ways of killing cancer cells without damaging healthy tissues and causing side effects. Targeted therapies are usually developed by finding a particular property unique to cancer cells – for example, a genetic mutation – and designing a drug to target that property. Most brain tumors are...